🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）

Recruitingn/aAges 18 Years - anyAllQian Chu
NCT07388771 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC. The core research question is: Can a multi-model approach predict outcomes of neoadjuvant therapy for non-small cell lung cancer and provide clinical recommendations?

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. pathologically diagnosed non-small cell lung cancer 2. The treatment plan is：receiving neoadjuvant chemo-immunotherapy during the study period, followed by surgical resection Exclusion Criteria: 1. recurrent or metastatic lung cancer; 2. patients with other primary tumors
💊

What it tests

  • Not listed
📍

Where

2 sites
Tongji hospital
Wuhan, China
Sir Run Run Shaw Hospital
Hangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy